Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 3285

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3285

License Grant
Licensor grants exclusive rights to develop, commercialize and market Rituxan outside the United States and Canada.
License Property
Rituximabis a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Field of Use
RITUXAN® (Rituximab) is indicated for the treatment of
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy

IPSCIO Record ID: 323411

License Grant
Pursuant to a spin-off in 2016, Licensor acquired rights relating to Ruxience (rituximab).
License Property
Ruxience® is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. When it attaches to CD20, rituximab helps destroy the B cells.
Field of Use
Ruxience is used in treatment for Non-Hodgkin’s Lymphoma (NHL) alone or with other chemotherapy medicines; Chronic Lymphocytic Leukemia (CLL) with the chemotherapy medicines fludarabine and cyclophosphamide; Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) with glucocorticoids.

Granulomatosis with polyangiitis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. Formerly called Wegener's granulomatosis, this condition is one of a group of blood vessel disorders called vasculitis. It slows blood flow to some of your organs.

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 190857

License Grant
Licensor announced that the Centers for Medicare and Medicaid Services established a unique, product-specific billing code, J-code (J9034), for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, a chemotherapy drug used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
License Property
The original license agreement is for BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 624

License Grant
The Licensee wishes to obtain access to the clinical data submitted by the German Licensor to the European Commission in support of the application to use the Product for the following indication.
License Property
The [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.

IPSCIO Record ID: 27461

License Grant
The agreement is to manufacture developmental, clinical and commercial quantities of anti-CD30 monoclonal antibody, which is a component of ADCETRIS. As part of the agreement the Licensor hereby grants an irrevocable, worldwide, nonexclusive license with the right to grant sublicenses, to each Licensor Invention which has been incorporated into the manufacturing process of the Bulk Drug Substance.
License Property
ADCETRIS®, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Licensee's proprietary technology.

The treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.

Field of Use
The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 372435

License Grant
Licensor grants an exclusive, non-transferable license, with the right to grant sublicenses, under the Licensor Technology, to Exploit the Compounds and the Products in the Field in the Territory.

Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.

License Property
Licensor has discovered and is developing a proprietary program that includes a Compound containing CD3 and CD19 specificities and is coded by Licensor as xx-011, with various potential human therapeutic uses.

Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.

DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.

DART Platform means Licensors proprietary platform for generating DARTs.

Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.

Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.

xx-011 is a humanized CD19 x CD3 bispecific DART protein.

Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.

The patents include
—  Covalent Diabodies And Uses Thereof;
—  Covalent Diabodies And Uses;
—  Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
—  CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
—  Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.

Field of Use
The development and commercialization agreement is for MGD011, a product candidate that incorporates our proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL).  These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.

The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans.  This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.

IPSCIO Record ID: 5086

License Grant
The Company entered into a license agreement with the Canadian University whereby it obtained an exclusive worldwide license (the CD77 License), with the right to grant sublicenses, to make, have made, use and sell any product using any method of selectively purging CD77 positive cells from bone marrow described in certain U.S. and PCT patent applications (U.S. Patent No. 5,801,145), and to use, have used, make and have made the method for treatment of Non-Hodgkin’s Lymphomas described in such applications (the Licensed CD77 Technology) for the purpose of producing products using the CD77 Technology (Licensed CD77 Products).
Field of Use
Although no assurance can be given, the Licensed CD77 Technology may lead to improved interventions for cancer patients whose therapies include autologous stem cell transplantation (ASCT).

Preliminary research indicates that stem cells may be removed from patients undergoing radiation or chemotherapy, and then transplanted back into the patient using the Licensed CD77 Technology.  Shiga-like toxin 1, a bacterial toxin, is used as an agent to selectively kill cancer cells in the patient’s bone marrow without harming the essential marrow cells which allow regeneration of marrow’s capacity for forming blood cells.

IPSCIO Record ID: 266238

License Grant
The Company and Swiss Licensee amended the  terms of the License Agreement to increase the U.S. royalty paid to the Company and re-allocate certain litigation expenses of BENDEKA net United States sales, provided that BENDEKA’s orphan drug exclusivity has not been rescinded, withdrawn or waived by such date.  The Amendment also extends the U.S. royalty term for BENDEKA until it is no longer sold in the United States. The previous royalty term was set to expire in 2025.
License Property
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
BENDEKA™, the Company’s bendamustine hydrochloride rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma.

IPSCIO Record ID: 26654

License Grant
We entered into an agreement giving us worldwide rights to use two proprietary hybridoma cell lines that are used in the production of BiovaxID with the University. These are the same cell lines that have been used by researchers at Stanford and the National Cancer Institute to perform their studies of the hybridoma idiotype vaccine in non-Hodgkins lymphoma. This agreement gives us exclusive rights to these cell lines through 2019 in the fields of B-cell and T-cell cancers, and it gives us non-exclusive rights in such fields of use at all times after 2019. The agreement also gives us the right to sublicense or transfer the licensed biological materials to collaborators in the licensed fields.
License Property
Biovaxid is a randomized phase III vaccine clinical research study being conducted at several cancer centers and clinics in the United States to compare two types of vaccine treatments for people with Stage III or IV follicular lymphoma — a type of cancer in the lymph nodes.
Field of Use
The rights granted apply to the medical field, primarily to cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.